4.4 Article

Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia

期刊

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 96, 期 8, 页码 1161-1169

出版社

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2010.039768

关键词

chronic lymphocytic leukemia; chronic lymphocytic leukemia; SNP-array; genomic aberrations; CNN-LOH; clonal evolution

资金

  1. Nordic Cancer Union
  2. Swedish Cancer Society
  3. Swedish Research Council
  4. Lion's Cancer Research Foundation, Uppsala, Sweden
  5. Svend Andersen Foundation, Denmark
  6. European Hematology Association [2006/18]

向作者/读者索取更多资源

Background High-resolution genomic microarrays enable simultaneous detection of copy-number aberrations such as the known recurrent aberrations in chronic lymphocytic leukemia [del(11q), del(13q), del(17p) and trisomy 12], and copy-number neutral loss of heterozygosity. Moreover, comparison of genomic profiles from sequential patients' samples allows detection of clonal evolution. Design and Methods We screened samples from 369 patients with newly diagnosed chronic lymphocytic leukemia from a population-based cohort using 250K single nucleotide polymorphism-arrays. Clonal evolution was evaluated in 59 follow-up samples obtained after 5-9 years. Results At diagnosis, copy-number aberrations were identified in 90% of patients; 70% carried known recurrent alterations, including del(13q) (55%), trisomy 12 (10.5%), del(11q) (10%), and del(17p) (4%). Additional recurrent aberrations were detected on chromosomes 2 (1.9%), 4 (1.4%), 8 (1.6%) and 14 (1.6%). Thirteen patients (3.5%) displayed recurrent copy-number neutral loss of heterozygosity on 13q, of whom 11 had concurrent homozygous del(13q). Genomic complexity and large 13q deletions correlated with inferior outcome, while the former was linked to poor-prognostic aberrations. In the follow-up study, clonal evolution developed in 8/24 (33%) patients with unmutated IGHV, and in 4/25 (16%) IGHV-mutated and treated patients. In contrast, untreated patients with mutated IGHV (n=10) did not acquire additional aberrations. The most common secondary event, del(13q), was detected in 6/12 (50%) of all patients with acquired alterations. Interestingly, aberrations on, for example, chromosome 6q, 8p, 9p and 10q developed exclusively in patients with unmutated IGHV. Conclusions Whole-genome screening revealed a high frequency of genomic aberrations in newly diagnosed chronic lymphocytic leukemia. Clonal evolution was associated with other markers of aggressive disease and commonly included the known recurrent aberrations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Analytical demands to use whole-genome sequencing in precision oncology

Manja Meggendorfer, Vaidehi Jobanputra, Kazimierz O. Wrzeszczynski, Paul Roepman, Ewart de Bruijn, Edwin Cuppen, Reinhard Buttner, Carlos Caldas, Sean Grimmond, Charles G. Mullighan, Olivier Elemento, Richard Rosenquist, Anna Schuh, Torsten Haferlach

Summary: Interrogating the tumor genome through whole-genome sequencing (WGS) has the potential to impact cancer diagnostics, prognostication, and therapy selection. This review emphasizes the requirements for implementing, validating, and maintaining a clinical WGS pipeline to obtain high-quality patient-specific data.

SEMINARS IN CANCER BIOLOGY (2022)

Article Oncology

Transcriptome sequencing of archived lymphoma specimens is feasible and clinically relevant using exome capture technology

Aron Skaftason, Ying Qu, Maysaa Abdulla, Jessica Nordlund, Mattias Berglund, Susanne Bram Ednersson, Per-Ola Andersson, Gunilla Enblad, Rose-Marie Amini, Richard Rosenquist, Larry Mansouri

Summary: This study used an exome capture-based RNA-sequencing protocol to explore gene expression in FF and FFPE samples from DLBCL patients, finding that despite fewer mapped reads, FFPE samples maintained similar gene expression to FF samples. Through clustering analysis and validation cohorts, the high consistency in gene expression between FF and FFPE samples was confirmed.

GENES CHROMOSOMES & CANCER (2022)

Review Medicine, General & Internal

Towards precision medicine in lymphoid malignancies

Marco M. Buhler, Jose Martin-Subero, Qiang Pan-Hammarstrom, Elias Campo, Richard Rosenquist

Summary: Histopathologic examination is important for the diagnosis of lymphoid malignancies, but recent advances in high-throughput technologies have improved our understanding of these tumors. Certain genomic alterations can provide diagnostic information and others can indicate prognosis or treatment response. Comprehensive molecular profiling may pave the way for precision diagnostics and medicine.

JOURNAL OF INTERNAL MEDICINE (2022)

Article Oncology

Precision diagnostics in lymphomas-Recent developments and future directions

Larry Mansouri, Birna Thorvaldsdottir, Stamatia Laidou, Kostas Stamatopoulos, Richard Rosenquist

Summary: Genetics plays a crucial role in the clinical diagnostics of lymphomas, helping to subclassify the disease and stratify patient risk. Recent advancements in high-throughput sequencing technologies have provided a detailed understanding of the genomic landscape of various lymphoma entities, revealing a diverse genetic background. These studies have improved our understanding of lymphoma ontogeny and evolution and have identified potential genetic markers that can enhance lymphoma diagnostics and prognostication. However, the number of gene mutations with predictive impact for treatment selection remains limited. This review highlights clinically relevant diagnostic, prognostic, and predictive markers in lymphomas and discusses the potential of comprehensive genomic characterization for precision diagnostics and tailored therapy strategies.

SEMINARS IN CANCER BIOLOGY (2022)

Article Hematology

Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study

Joel Joelsson, Tove Wasterlid, Richard Rosenquist, Lasse Hjort Jakobsen, Tarec C. El-Galaly, Karin E. Smedby, Sandra Eloranta

Summary: Considering the changes in treatment and prognosis for non-Hodgkin lymphoma (NHL), understanding long-term health outcomes and treatment-related complications has become increasingly important. This study investigates the time trends of second primary malignancies (SPMs) in Swedish NHL patients, both before and after the introduction of anti-CD20 antibody therapy. The findings indicate that NHL survivors have a higher risk of solid tumors and hematologic malignancies, particularly myelodysplastic syndrome/acute myeloid leukemia. The study also suggests that modern treatment standards are not associated with modified SPM risk, but nonchemotherapy-based treatments may help reduce the risk of myelodysplastic syndrome/acute myeloid leukemia in follicular lymphoma patients.

BLOOD ADVANCES (2022)

Article Hematology

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

Eugen Tausch, Viktor Ljungstrom, Andreas Agathangelidis, Marc Zapatka, Lydia Scarfo, Billy Michael Chelliah Jebaraj, Deyan Y. Yosifov, Annika Mueller, Veerendra Munugalavadla, Jeremiah D. Degenhardt, Paolo Ghia, Richard Rosenquist, Stephan Stilgenbauer

Article Hematology

International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia

Simone Oerlemans, Fabio Efficace, Jacobien M. Kieffer, Charalampia Kyriakou, Aliki Xochelli, Kerstin Levedahl, Duska Petranovic, Fabio Cardoso Borges, Anne Bredart, Omar Shamieh, Laimonas Gziskevicius, Jens Lehmann, Christian W. Scholz, Giovanni Caocci, Stefano Molica, Kostas Stamatopoulos, Alkistis-Kyra Panteliadou, Maria Papaioannou, Waleed Alrjoob, Panagiotis Baliakas, Richard Rosenquist, Sandra Malak, Ana Miranda, Kim Cocks, Lonneke van de Poll-Franse

Summary: This international study tested the psychometric properties of a newly developed measure for CLL patients and found that it can increase sensitivity of HRQoL assessment and provide better guidance for treatment decision-making.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Review Oncology

Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL

Andreas Agathangelidis, Anastasia Chatzidimitriou, Thomas Chatzikonstantinou, Cristina Tresoldi, Zadie Davis, Veronique Giudicelli, Sofia Kossida, Chrysoula Belessi, Richard Rosenquist, Paolo Ghia, Anton W. Langerak, Frederic Davi, Kostas Stamatopoulos

Summary: The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is critical for assessing prognosis and responses to therapy in patients with chronic lymphocytic leukemia (CLL). Immunogenetic analysis in CLL has also revealed distinct subsets of patients based on (quasi)identical B cell receptor immunoglobulin (BcR IG), which display consistent biology, clinical presentation, and outcome. As a cornerstone for accurate risk stratification and clinical decision making, immunogenetic analysis in CLL requires robust methodologies, including next generation sequencing (NGS).

LEUKEMIA (2022)

Editorial Material Oncology

Precision medicine in cancer: A paradigm shift

Richard Rosenquist, Stefan Frohling, Kostas Stamatopoulos

SEMINARS IN CANCER BIOLOGY (2022)

Article Medicine, General & Internal

A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias

Eva Berglund, Gisela Barbany, Christina Orsmark-Pietras, Linda Fogelstrand, Jonas Abrahamsson, Irina Golovleva, Helene Hallbook, Martin Hoglund, Vladimir Lazarevic, Lars-Ake Levin, Jessica Nordlund, Ulrika Noren-Nystrom, Josefine Palle, Tharshini Thangavelu, Lars Palmqvist, Valtteri Wirta, Lucia Cavelier, Thoas Fioretos, Richard Rosenquist, Clinical Genomics Platform SciLifeLab Genomic Med Sweden

Summary: This national multi-center study aims to evaluate the technical feasibility and efficiency of using whole-genome sequencing and whole-transcriptome sequencing as a diagnostic tool for patients with acute lymphoblastic leukemia and acute myeloid leukemia. The study comprises four phases and will involve approximately 700 patients, with endpoints including diagnostic efficiency, clinical feasibility, and health-economic impact.

FRONTIERS IN MEDICINE (2022)

Article Oncology

Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study

Cecilia Arthur, Fatemah Rezayee, Nina Mogensen, Leonie Saft, Richard Rosenquist, Magnus Nordenskjold, Arja Harila-Saari, Emma Tham, Gisela Barbany

Summary: This study demonstrates that whole-genome sequencing of genetic information in children with ALL, combined with ddPCR quantification, can accurately assess MRD levels. In addition, cfDNA extracted from plasma and cerebrospinal fluid can provide valuable information about MRD and low-grade CNS involvement.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Matthew Kaufman, Xiao-Jie Yan, Wentian Li, Emanuela M. Ghia, Anton W. Langerak, Laura Z. Rassenti, Chrysoula Belessi, Neil E. Kay, Frederic Davi, John C. Byrd, Sarka Pospisilova, Jennifer R. Brown, Mark Catherwood, Zadie Davis, David Oscier, Marco Montillo, Livio Trentin, Richard Rosenquist, Paolo Ghia, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Kostas Stamatopoulos, Thomas J. Kipps, Donna Neuberg, Nicholas Chiorazzi

Summary: Patients with mutated IGHV genes (M-CLL) have better outcomes, possibly due to suppressed BCR signaling that no longer delivers trophic signals to leukemic B cells.

FRONTIERS IN ONCOLOGY (2022)

Article Hematology

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco D'Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, Jose Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Summary: With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. However, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper discusses how established and newly developed molecular testing technologies complement clinical diagnoses and contribute to refining diagnosis, risk stratification, and therapy prediction for lymphoid neoplasms. Future methods such as whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling are likely to become important tools for implementing precision medicine approaches in clinical decision making for lymphoid malignancies.
Letter Biochemistry & Molecular Biology

Implementing precision medicine in a regionally organized healthcare system in Sweden

Thoas Fioretos, Valtteri Wirta, Lucia Cavelier, Eva Berglund, Mikaela Friedman, Michael Akhras, Johan Botling, Hans Ehrencrona, Lars Engstrand, Gisela Helenius, Therese Fagerqvist, David Gisselsson, Sofia Gruvberger-Saal, Ulf Gyllensten, Markus Heidenblad, Kina Hoglund, Bo Jacobsson, Maria Johansson, Asa Johansson, Maria Johansson Soller, Marene Landstrom, Par Larsson, Lars-Ake Levin, Anna Lindstrand, Lovisa Lovmar, Anna Lyander, Malin Melin, Ann Nordgren, Gunnel Nordmark, Paula Molling, Lars Palmqvist, Richard Palmqvist, Dirk Repsilber, Per Sikora, Bianca Stenmark, Peter Soderkvist, Henrik Stranneheim, Tobias Strid, Craig E. Wheelock, Mia Wadelius, Anna Wedell, Anders Edsjo, Richard Rosenquist

NATURE MEDICINE (2022)

Article Oncology

Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany

Albrecht Stenzinger, Anders Edsjoe, Carolin Ploeger, Mikaela Friedman, Stefan Frohling, Valtteri Wirta, Thomas Seufferlein, Johan Botling, Justus Duyster, Michael Akhras, Robert Thimme, Thoas Fioretos, Michael Bitzer, Lucia Cavelier, Peter Schirmacher, Nisar Malek, Richard Rosenquist

Summary: In recent decades, advancements in technology and science have led to the integration of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies. Precision medicine, exemplified by precision oncology, holds great promise in various medical fields. Dedicated healthcare centers are required for the real-world implementation of precision medicine, gathering interdisciplinary expertise. Networks of such centers, like Genomic Medicine Sweden and the Centers for Personalized Medicine initiative in Germany, aim to provide a comprehensive framework for precision medicine. They seek to cover all aspects, from technology development to involvement of stakeholders, in order to ensure the sustainable and widespread implementation of precision medicine.

SEMINARS IN CANCER BIOLOGY (2022)

暂无数据